Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RGS12 | O14924 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9402140 | 0.91 | MAPT (0.41) | TSHRBACE1TDP1RGS12ALDH1A1 | |
| SCHEMBL7061475 | 0.89 | MAPT (0.44) | TSHRBACE1TDP1RGS12ALDH1A1 | |
| SCHEMBL9402183 | 0.89 | MAPT (0.44) | TSHRBACE1TDP1RGS12ALDH1A1 | |
| SCHEMBL16640292 | 0.89 | MAPT (0.44) | TSHRBACE1TDP1RGS12ALDH1A1 | |
| SCHEMBL2755248 | 0.87 | TSHR (0.37) | TSHRBACE1TDP1MAPT | |
| SCHEMBL3168007 | 0.85 | TSHR (0.35) | TSHRBACE1TDP1 | |
| SCHEMBL25389707 | 0.84 | TDP1 (0.33) | TSHRBACE1TDP1 | |
| SCHEMBL13593994 | 0.84 | TSHR (0.36) | TSHRBACE1ALDH1A1MAPT | |
| SCHEMBL13163013 | 0.84 | PLG (0.37) | TSHRBACE1RGS12 | |
| SCHEMBL30522541 | 0.84 | TDP1 (0.33) | TSHRBACE1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD (CN) | 2024-09-12 | — | — | US | disclosed |
| CN-113754635-B | Condensed ring compound and preparation method and application thereof | 成都康弘药业集团股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-115720578-A | Tricyclic derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-4100005-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022212638-A1 | PRODRUGS OF ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2022-10-06 | — | — | WO | disclosed |
| CN-115052596-A | ADAMTS inhibitor, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-1200392-A1 | PROCESS FOR THE PREPARATION OF CYCLOPROPYLGLYCINE | EASTMAN CHEMICAL COMPANY (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6191306-B1 | USING 5-STEP PROCESS WHEREIN CYCLOPROPANECARBOXALDEHYDE IS REACTED WITH A-AMINOALKYLAROMATIC COMPOUND TO OBTAIN IMINE WHICH IS REACTED WITH CYANIDE TO PRODUCE AMINONITRILE WHICH IS HYDROLYZED TO THE CORRESPONDING ACID WHICH IS HYDROGENATED | EASTMAN CHEMICAL COMPANY | 2001-02-20 | — | — | US | disclosed |
| WO-2001009084-A1 | PROCESS FOR THE PREPARATION OF CYCLOPROPYLGLYCINE | EASTMAN CHEMICAL COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| US-6103929-A | Process for the preparation of cyclopropylglycine | EASTMAN CHEMICAL COMPANY (US) | 2000-08-15 | — | — | US | disclosed |
| US-6090982-A | Process for the preparation of cyclopropylglycine | EASTMAN CHEMICAL COMPANY (US) | 2000-07-18 | — | — | US | disclosed |
| US-5338859-A | Reacting a hydantoin with a calcium base; crystallization; precipitation; separation | HOECHST CELANESE CORPORATION (US) | 1994-08-16 | — | — | US | disclosed |
| US-4436910-A | SAPONIFICATION | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1984-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | ADAMTS5, ADAMTS4, ADAMTS1 | TSHR 4181/4885BACE1 819/4885TDP1 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.